Online inquiry

IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8057MR)

This product GTTS-WQ8057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8057MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8021MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ3994MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ50MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ13407MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ13372MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ8713MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ3254MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ4376MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW